{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-071180","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.019189+00:00","generated_at":"2026-06-14T00:52:41.945611+00:00","sec_items":["5.02","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cyclacel annual meeting results: equity plan increase approved, directors re-elected, preferred dividend declared","bullets":["Stockholders approved 900,000-share increase to 2018 Equity Incentive Plan.","Spiro Rombotis and Dr. Brian Schwartz re-elected as Class 2 directors for term to 2026.","RSM US LLP ratified as independent auditor for FY2023.","Advisory vote on executive compensation passed (52% support with many abstentions and broker non-votes).","Board declared $0.15/share quarterly dividend on preferred stock (CYCCP), payable Aug 1 to holders of record July 21."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-071180","json":"https://secwatch.observer/filing/0001104659-23-071180.json","markdown":"https://secwatch.observer/filing/0001104659-23-071180.md","text":"https://secwatch.observer/filing/0001104659-23-071180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/0001104659-23-071180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/tm2318711d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:52:41.945611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b98bcbb48bcbd48ad1b01ae9730ab9603f9be3a","claim":"Bio Green Med Solution, Inc. shareholders approved Election of Dr. Samuel L. Barker as a Class 2 director by holders of Preferred Stock.","evidence_excerpt":"Votes of the preferred stockholders regarding the election of Dr. Samuel L. Barker as a Class 2 director were as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/0001104659-23-071180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"2e1987125aacddcc20c72bb735539de0045cddc8","claim":"Bio Green Med Solution, Inc. shareholders approved Approval of an amendment to the Company's 2018 Equity Incentive Plan.","evidence_excerpt":"Votes of the common stockholders regarding the approval of an amendment to the Company's 2018 Equity Incentive Plan were as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/0001104659-23-071180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"659919d5f35156e7431f23274c304fed83e7e6ad","claim":"Bio Green Med Solution, Inc. shareholders approved Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.","evidence_excerpt":"Votes of the common stockholders, on an advisory basis, regarding the executive compensation of the Company's named executive officers, as disclosed in the Company's proxy statement, were as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/0001104659-23-071180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"9e0dc2539a6af97aecb3c6f59752e9304acd741f","claim":"Bio Green Med Solution, Inc. shareholders approved Ratification of the selection of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-12-31 meeting.","evidence_excerpt":"Votes of the common stockholders regarding the ratification of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 were as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/0001104659-23-071180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"de0e980599fffacf9c4cba6e017aa6a8e988e854","claim":"Bio Green Med Solution, Inc. shareholders approved Re-election of two Class 2 directors to the Company's board of directors.","evidence_excerpt":"Votes of the common stockholders regarding the election of the Class 2 director nominees were as follows:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923071180/0001104659-23-071180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}